Standard BioTools
Standard BioTools Q3 2024 Revenues Fall 5 Percent
The company posted total revenues of $45.0 million, down from pro forma revenues of $47.4 million in Q3 2023 but beating the consensus Wall Street estimate of $41.0 million.
Standard BioTools Lowers Full-Year Revenue Guidance as Q2 Revenues Fall 23 Percent
SomaScanassay services experienced service contract delays in Q2, impacting instrument sales, CEO Michael Egholm said.
Standard BioTools Q1 Revenues Grow 81 Percent After SomaLogic Merger
Revenues grew 2 percent year over year on a pro forma basis following the completion of the merger with SomaLogic in early January.
In Brief This Week: SomaLogic, Standard BioTools, Qiagen, Geneseeq
News items for the week of Jan. 1, 2024.
SomaLogic Cofounder and former CEO Larry Gold and Chief Technology Officer Jason Cleveland have filed a class action suit, accusing the board of breach of fiduciary duty.